ArticleInternational journal of clinical and experimental medicine2015
Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Position statement on the diagnosis and management of non-alcoholic fatty liver disease.Saudi medical journal · 2019Pooled it
- Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2019Pooled it
- Does whey protein supplementation during resistance exercise have additional benefits for decreasing hepatic fat content?Journal of the International Society of Sports Nutrition · 2023Trial
- Trial
- Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients.Oxidative medicine and cellular longevity · 2019Trial
- Metabolic dysfunction-associated steatotic liver disease in cushing's syndrome: a case controlled FibroScan study.Journal of endocrinological investigation · 2026Article
- The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging.Journal of endocrinological investigation · 2026Article
- Optimized CAP cut-offs for metabolic dysfunction associated steatotic liver disease in patients living with obesity: a large biopsy-based prospective study.Scientific reports · 2026Article
- Advances in quantitative ultrasound for metabolic dysfunction-associated steatotic liver disease diagnosis.Frontiers in physiology · 2026Review
- Life-course BMI trajectories and long-term weight gain in relation to hepatic steatosis in a rural community-based cohort in Southwest China.Frontiers in public health · 2026Article
- Development of Cost-Effective Fatty Liver Disease Prediction Models in a Chinese Population: Statistical and Machine Learning Approaches.JMIR formative research · 2024Article
- Steatotic Liver Disease and Sepsis Outcomes-A Prospective Cohort Study (SepsisFAT).Journal of clinical medicine · 2024Article
- Prevalence Study of MASLD in Adolescent and Young Adult Pacific Islanders and Asians Living in Hawai'i.Journal of the Endocrine Society · 2024Article
- Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C.Digestive diseases and sciences · 2023Article
- Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease.Hepatology forum · 2023Article
- Do Semaphorins Play a Role in Development of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease?Biomedicines · 2022Article
- Vibration-controlled Transient Elastography in NAFLD: Review Study.Euroasian journal of hepato-gastroenterology · 2022Review
- Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP).Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Controlled attenuation parameter measured using transient elastography for the noninvasive assessment of macrovesicular steatosis in potential living liver donors.Ultrasonography (Seoul, Korea) · 2022Article
- Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography.International urology and nephrology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimto evaluate the performance and accuracy of Controlled attenuation parameter CAP for hepatic steatosis detection.
methodsPubMed, EBSCO, Elsevier Science, Ovid, and Wiley were selected to search studies until August 31, 2014. Quality Assessment of Diagnostic Accuracy Studies checklist was used to assess the quality of included studies. Heterogeneity was evaluated using Q test. Sensitivity, specificity, diagnostic odds ratio (DOR), and the area under curve (AUC) with its 95% confidence intervals (CIs) were calculated to evaluate the accuracy of CAP for assessment of hepatic steatosis stage (≥ S1, ≥ S2 and ≥ S3).
resultsTotally 11 studies (13 cohorts) with high methodological qualities were identified. The summary point estimations with 95% CIs of sensitivity, specificity, AUC and DORs were 0.78 (0.71, 0.84), 0.79 (0.70, 0.86), 0.86 (0.82, 0.88), and 14 (7, 27) for ≥ S1; 0.82 (0.74, 0.88), 0.79 (0.73, 0.85), 0.88 (0.85, 0.90) and 18 (10, 30) for ≥ S2; 0.86 (0.82, 0.89), 0.89 (0.86, 0.92), 0.94 (0.91, 0.96) and 51 (35, 76) for ≥ S3. Significant heterogeneity was found among the studies in ≥ S1 and ≥ S3. Threshold effect was existed in ≥ S3, but not in ≥ S1 and ≥ S2. Publication bias was not existed in ≥ S1 and ≥ S2 except ≥ S3.
conclusionCAP provides good sensitivity and specificity for detection of ≥ S1, ≥ S2, and ≥ S3 steatosis. However, future studies with large samples are still necessary to confirm the clinical application.
Indexed as
Identifiers
26770355PMC4694255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.